Published in Nat Rev Cardiol on March 01, 2010
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. Sci Transl Med (2011) 1.78
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther (2011) 0.94
TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes. Cell Physiol Biochem (2011) 0.90
Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther (2013) 0.89
Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol (2012) 0.88
Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther (2011) 0.86
Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm (2010) 0.84
Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83
Potassium currents in the heart: Functional roles in repolarization, arrhythmia and therapeutics. J Physiol (2016) 0.79
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vasc Health Risk Manag (2013) 0.78
Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine. Front Pharmacol (2013) 0.78
Synthesis of a highly water-soluble acacetin prodrug for treating experimental atrial fibrillation in beagle dogs. Sci Rep (2016) 0.76
Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol (2011) 0.76
Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol (2012) 0.75
Application of Traditional Chinese Medicine in Treatment of Atrial Fibrillation. Evid Based Complement Alternat Med (2017) 0.75
Advances in the Pharmacological Treatment of Atrial Fibrillation. Curr Med Lit Cardiol (2010) 0.75
Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure. J Vet Intern Med (2015) 0.75
Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Male Subjects: An Open-Label Phase I Clinical Study. Eur J Drug Metab Pharmacokinet (2017) 0.75
Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med (1989) 9.08
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev (2004) 5.79
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Amiodarone for atrial fibrillation. N Engl J Med (2007) 4.52
Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation (2008) 4.43
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med (2004) 4.19
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol (1999) 3.57
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation (2004) 3.44
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet (2000) 3.36
Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res (2004) 3.30
Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol (2008) 3.26
Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation (2002) 3.22
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet (2006) 3.15
N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol (2005) 3.12
Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol (2009) 3.09
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
Transmural dispersion of myofiber mechanics: implications for electrical heterogeneity in vivo. J Am Coll Cardiol (2007) 2.44
Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res (1997) 2.26
Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation (2005) 2.15
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res (2004) 2.06
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 1.99
Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov (2006) 1.98
Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation (2004) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol (2004) 1.92
Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res (2000) 1.82
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation (2004) 1.77
The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation (2005) 1.77
Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg (2009) 1.72
Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol (2008) 1.70
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J (2007) 1.69
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J (2008) 1.64
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J (2009) 1.63
Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation (2008) 1.61
Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res (1999) 1.61
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg (2009) 1.59
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation (2001) 1.51
"Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation (2004) 1.48
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol (2007) 1.42
Novel approaches for pharmacological management of atrial fibrillation. Drugs (2009) 1.32
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation (2006) 1.26
The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J (2008) 1.25
Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol (2002) 1.25
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol (2007) 1.21
Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol. J Cardiovasc Pharmacol (1992) 1.21
The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J (2009) 1.21
Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol (2003) 1.20
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace (2008) 1.19
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol (2006) 1.17
Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol (2008) 1.15
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5. Circ Res (2009) 1.15
Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol (2004) 1.14
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation (2006) 1.13
Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol (1998) 1.12
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Dronedarone for atrial fibrillation--an odyssey. N Engl J Med (2009) 1.12
Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol (2008) 1.08
Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol (1998) 1.08
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev (2007) 1.07
Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res (2007) 1.06
Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation (2003) 1.06
Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol (1982) 1.05
Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs (2007) 1.04
Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol (2009) 1.04
Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation (2007) 1.02
In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther (2005) 1.02
New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol (2009) 1.02
Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res (2007) 1.02
Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res (2006) 1.02
Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol (2003) 1.01
New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol (2008) 0.99
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 1.86
Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res (2004) 1.85
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol (2006) 1.78
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm (2006) 1.74
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation (2011) 1.60
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol (2010) 1.60
Early repolarization syndrome: a decade of progress. J Electrocardiol (2013) 1.59
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol (2004) 1.53
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm (2006) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm (2011) 1.46
Resolving the M-cell debate: why and how. Heart Rhythm (2011) 1.45
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm (2008) 1.42
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J (2011) 1.37
Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol (2004) 1.35
Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol (2007) 1.32
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol (2003) 1.31
Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf (2008) 1.30
Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol (2007) 1.28
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm (2008) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One (2012) 1.23
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
The role of local voltage potentials in outflow tract ectopy. Europace (2010) 1.20
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
M cells in the human heart. Circ Res (2010) 1.17
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation (2006) 1.16
Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol (2005) 1.15
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation (2004) 1.14
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol (2009) 1.11
Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A (2011) 1.11
Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol (2005) 1.11
Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol (2002) 1.10
HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol (2003) 1.09
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09
The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol (2002) 1.08
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation (2006) 1.08